BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319-330. [PMID: 16842459 DOI: 10.1111/j.1365-2036.2006.02974.x] [Cited by in Crossref: 133] [Cited by in F6Publishing: 121] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Han R, Xiao Y, Bai Q, Jonathan Choi CH. Self-therapeutic metal-based nanoparticles for treating inflammatory diseases. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.07.009] [Reference Citation Analysis]
2 Hu X, Yang F, Hashmi MF. Analysis of the Therapeutic Effect of Changyanning on Intestinal Flora in Inflammatory Bowel Disease. Contrast Media & Molecular Imaging 2022;2022:1-8. [DOI: 10.1155/2022/3757763] [Reference Citation Analysis]
3 Wickramasekera N, Coates E, Barr A, Lee MJ, Blackwell S, Bedford H, Dames N, Sebastian S, Probert C, Shackley P, Lobo AJ. Patient preferences for treatment in steroid resistant ulcerative colitis - a discrete-choice experiment. Scand J Gastroenterol 2022;:1-10. [PMID: 35142585 DOI: 10.1080/00365521.2022.2036808] [Reference Citation Analysis]
4 Falloon KA, Fiocchi C. Current Therapy in Inflammatory Bowel Disease: Why and How We Need to Change? EMJ Innov. [DOI: 10.33590/emjinnov/21-00134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut 2021:gutjnl-2021-326390. [PMID: 34937767 DOI: 10.1136/gutjnl-2021-326390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Cichoż-Lach H, Michalak A, Kopertowska-Majchrzak M, Eder P, Stawczyk-Eder K, Waszak K, Talar-Wojnarowska R, Zatorski H, Solarska-Półchłopek A, Chmielnicki J, Filip R, Pękala A, Janiak M, Skrobot K, Kasińska E, Krogulecki M, Królikowski P, Kłopocka M, Liebert A, Poniewierka E, Smoła I, Gąsiorowska A, Kaczka A, Wypych J, Wojciechowski K, Drygała S, Zagórowicz E. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therap Adv Gastroenterol 2021;14:17562848211036456. [PMID: 34484422 DOI: 10.1177/17562848211036456] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Guo D, Jiang K, Hong J, Zhang M, Shi Y, Zhou B. Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis. Int J Colorectal Dis 2021;36:2081-92. [PMID: 34467414 DOI: 10.1007/s00384-021-04017-2] [Reference Citation Analysis]
8 Yang ZH, Liu F, Zhu XR, Suo FY, Jia ZJ, Yao SK. Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis. World J Gastroenterol 2021; 27(24): 3609-3629 [PMID: 34239273 DOI: 10.3748/wjg.v27.i24.3609] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
9 Yadav V, Mai Y, McCoubrey LE, Wada Y, Tomioka M, Kawata S, Charde S, Basit AW. 5-Aminolevulinic Acid as a Novel Therapeutic for Inflammatory Bowel Disease. Biomedicines 2021;9:578. [PMID: 34065300 DOI: 10.3390/biomedicines9050578] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
10 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Tanaka M, Takagi T, Naito Y, Uchiyama K, Hotta Y, Toyokawa Y, Kashiwagi S, Kamada K, Ishikawa T, Yasuda H, Konishi H, Itoh Y. Low serum albumin at admission is a predictor of early colectomy in patients with moderate to severe ulcerative colitis. JGH Open 2021;5:377-81. [PMID: 33732885 DOI: 10.1002/jgh3.12506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Konidari A, Dickens D, Pirmohamed M. Inflammatory Bowel Disease: A Personalized Approach. Front Pediatr 2020;8:620545. [PMID: 33643966 DOI: 10.3389/fped.2020.620545] [Reference Citation Analysis]
13 Schulberg JD, Wright EK, Holt BA, Wilding HE, Hamilton AL, Ross AL, Kamm MA. Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review. J Gastroenterol Hepatol 2021;36:344-61. [PMID: 33150989 DOI: 10.1111/jgh.15330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
15 George LA, Cross RK. Treatment of Ulcerative Colitis with Steroids (in Whom, How Long, What Dose, What Form). Gastroenterology Clinics of North America 2020;49:705-16. [DOI: 10.1016/j.gtc.2020.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Coelho MR, Romi MD, Ferreira DMTP, Zaltman C, Soares-Mota M. The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials. Nutrients. 2020;12. [PMID: 32751776 DOI: 10.3390/nu12082296] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
17 Sood A, Ahuja V, Midha V, Sinha SK, Pai CG, Kedia S, Mehta V, Bopanna S, Abraham P, Banerjee R, Bhatia S, Chakravartty K, Dadhich S, Desai D, Dwivedi M, Goswami B, Kaur K, Khosla R, Kumar A, Mahajan R, Misra SP, Peddi K, Singh SP, Singh A. Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. Intest Res 2020;18:355-78. [PMID: 32646198 DOI: 10.5217/ir.2019.09176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Editorial A. CROHN'S DISEASE. CLINICAL RECOMMENDATIONS (PRELIMINARY VERSION). Koloproktologiâ 2020;19:8-38. [DOI: 10.33878/2073-7556-2020-19-2-8-38] [Cited by in Crossref: 25] [Cited by in F6Publishing: 2] [Article Influence: 12.5] [Reference Citation Analysis]
19 Porter RJ, Kalla R, Ho GT. Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Res 2020;9:F1000 Faculty Rev-294. [PMID: 32399194 DOI: 10.12688/f1000research.20805.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
20 Einwächter H. Current Concepts of Pharmacotherapy in Crohn's Disease. Visc Med 2019;35:344-7. [PMID: 31934581 DOI: 10.1159/000504101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Lee H, Schneider Y, Lichtenstein GR. Going Third Class: Treatment of Steroid-Dependent Ulcerative Colitis. Dig Dis Sci 2019;64:1138-41. [PMID: 31016561 DOI: 10.1007/s10620-019-05610-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Lorén V, Garcia-Jaraquemada A, Naves JE, Carmona X, Mañosa M, Aransay AM, Lavin JL, Sánchez I, Cabré E, Manyé J, Domènech E. ANP32E, a Protein Involved in Steroid-Refractoriness in Ulcerative Colitis, Identified by a Systems Biology Approach. J Crohns Colitis 2019;13:351-61. [PMID: 30329026 DOI: 10.1093/ecco-jcc/jjy171] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
23 Salice M, Rizzello F, Calabrese C, Calandrini L, Gionchetti P. A current overview of corticosteroid use in active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2019;13:557-61. [PMID: 30947569 DOI: 10.1080/17474124.2019.1604219] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
24 Macaluso FS, Cavallaro F, Felice C, Mazza M, Armuzzi A, Gionchetti P, Vecchi M, Orlando A. Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. Dig Liver Dis 2019;51:613-20. [PMID: 30826279 DOI: 10.1016/j.dld.2019.01.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
25 Mahmud-Al-Rafat A, Majumder A, Taufiqur Rahman KM, Mahedi Hasan AM, Didarul Islam KM, Taylor-Robinson AW, Billah MM. Decoding the enigma of antiviral crisis: Does one target molecule regulate all? Cytokine 2019;115:13-23. [PMID: 30616034 DOI: 10.1016/j.cyto.2018.12.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
26 Leoncini G, Villanacci V, Marin MG, Crisafulli V, Cadei M, Antonelli E, Leoci C, Bassotti G. Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy. Tech Coloproctol. 2018;22:941-946. [PMID: 30535522 DOI: 10.1007/s10151-018-1896-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
27 Sharara AI, Al Awadhi S, Alharbi O, Al Dhahab H, Mounir M, Salese L, Singh E, Sunna N, Tarcha N, Mosli M. Epidemiology, disease burden, and treatment challenges of ulcerative colitis in Africa and the Middle East. Expert Rev Gastroenterol Hepatol. 2018;12:883-897. [PMID: 30096985 DOI: 10.1080/17474124.2018.1503052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
28 Vedamurthy A, Xu L, Luther J, Colizzo F, Garber JJ, Khalili H, Ananthakrishnan AN. Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis. Dig Dis Sci 2018;63:2740-6. [PMID: 29951797 DOI: 10.1007/s10620-018-5176-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
29 Barreiro-Alonso E, Saro-Gismera C, Sánchez M. Outcomes and prediction of corticosteroid therapy after successive courses of ulcerative colitis treatments. Expert Rev Gastroenterol Hepatol 2018;12:733-41. [PMID: 29911903 DOI: 10.1080/17474124.2018.1489231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
30 Khan N, Trivedi C, Shah Y, Cole E, Lewis J, Yang Y. The Natural History of Newly Diagnosed Ulcerative Colitis in Patients with Concomitant Primary Sclerosing Cholangitis. Inflammatory Bowel Diseases 2018;24:2062-7. [DOI: 10.1093/ibd/izy106] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
31 Jeuring SFG, Biemans VBC, van den Heuvel TRA, Zeegers MP, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Masclee AAM, Jonkers DMAE, Pierik MJ. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era—Results from the Dutch Population-Based IBDSL Cohort. American Journal of Gastroenterology 2018;113:384-95. [DOI: 10.1038/ajg.2017.482] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
32 Bezzio C, Festa S, Zerboni G, Papi C, Manes G, Saibeni S. A safety evaluation of budesonide MMX for the treatment of ulcerative colitis. Expert Opinion on Drug Safety 2018;17:437-44. [DOI: 10.1080/14740338.2018.1442432] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Khan N, Patel D, Shah Y, Trivedi C, Yang YX. Albumin as a prognostic marker for ulcerative colitis. World J Gastroenterol 2017; 23(45): 8008-8016 [PMID: 29259376 DOI: 10.3748/wjg.v23.i45.8008] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
34 Dubois-Camacho K, Ottum PA, Franco-Muñoz D, De la Fuente M, Torres-Riquelme A, Díaz-Jiménez D, Olivares-Morales M, Astudillo G, Quera R, Hermoso MA. Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. World J Gastroenterol 2017; 23(36): 6628-6638 [PMID: 29085208 DOI: 10.3748/wjg.v23.i36.6628] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 57] [Article Influence: 13.6] [Reference Citation Analysis]
35 Asl Baakhtari S, Mccombie A, ten Bokkel Huinink S, Irving P, Siegel CA, Mulder R, Mulder CJ, Gearry R. Observational Study of Perspectives of Inflammatory Bowel Disease Patients Concerning the Use of Corticosteroids. Dig Dis 2017;36:33-9. [DOI: 10.1159/000478772] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
36 Iida T, Ikeya K, Kato M, Abe J, Yamamoto M, Watanabe F, Sugimoto K, Hanai H. Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice. Digestion. 2017;96:119-126. [PMID: 28796990 DOI: 10.1159/000479502] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
37 Khan N, Patel D, Shah Y, Lichtenstein G, Yang Y. A Novel User-Friendly Model to Predict Corticosteroid Utilization in Newly Diagnosed Patients with Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:991-7. [DOI: 10.1097/mib.0000000000001080] [Cited by in Crossref: 8] [Article Influence: 1.6] [Reference Citation Analysis]
38 Lightner AL, Shen B. Perioperative use of immunosuppressive medications in patients with Crohn's disease in the new "biological era". Gastroenterol Rep (Oxf) 2017;5:165-77. [PMID: 28852521 DOI: 10.1093/gastro/gow046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
39 Peyrin-biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X. French national consensus clinical guidelines for the management of Crohn’s disease. Digestive and Liver Disease 2017;49:368-77. [DOI: 10.1016/j.dld.2016.12.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
40 Rai T, Choudhury BN, Kedia S, Bopanna S, Venigalla PM, Garg SK, Singla V, Makharia G, Ahuja V. Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience. Dig Dis Sci. 2017;62:1025-1034. [PMID: 28161855 DOI: 10.1007/s10620-017-4450-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
41 Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.Dig Liver Dis. 2017;49:604-617. [PMID: 28254463 DOI: 10.1016/j.dld.2017.01.161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
42 Macaluso FS, Renna S, Orlando A, Cottone M. The biologics of ulcerative colitis. Expert Opinion on Biological Therapy 2016;17:175-84. [DOI: 10.1080/14712598.2017.1271871] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zhou Y, He H, Wang P, Zhang T, Lin M, Wang H, Nie Y, Chen Y. Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study. Eur J Gastroenterol Hepatol 2015;27:1270-5. [PMID: 26275085 DOI: 10.1097/MEG.0000000000000447] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
44 Lin CC, Wei SC, Lin BR, Tsai WS, Chen JS, Hsu TC, Lin WC, Huang TY, Chao TH, Lin HH, Wong JM, Lin JK. A retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease. Intest Res 2016;14:248-57. [PMID: 27433147 DOI: 10.5217/ir.2016.14.3.248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
45 To N, Ford AC, Gracie DJ. Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. Aliment Pharmacol Ther. 2016;44:117-126. [PMID: 27193202 DOI: 10.1111/apt.13663] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
46 Safroneeva E, Vavricka SR, Fournier N, Straumann A, Rogler G, Schoepfer AM. Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. Inflamm Bowel Dis. 2015;21:1348-1358. [PMID: 25806845 DOI: 10.1097/mib.0000000000000368] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
47 Leitner GC, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther 2016; 7(1): 5-20 [PMID: 26855808 DOI: 10.4292/wjgpt.v7.i1.5] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
48 Nuki Y, Esaki M, Asano K, Maehata Y, Umeno J, Moriyama T, Nakamura S, Matsumoto T, Kitazono T. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. Scand J Gastroenterol. 2016;51:700-705. [PMID: 26818468 DOI: 10.3109/00365521.2016.1138239] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
49 Endo K, Onodera M, Shiga H, Kuroha M, Kimura T, Hiramoto K, Kakuta Y, Kinouchi Y, Shimosegawa T. A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. Gastroenterol Res Pract. 2016;2016:3162595. [PMID: 26904108 DOI: 10.1155/2016/3162595] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
50 Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015;9:156-163. [PMID: 25518058 DOI: 10.1093/ecco-jcc/jju016] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
51 Armuzzi A, Gionchetti P, Daperno M, Danese S, Orlando A, Lia Scribano M, Vecchi M, Rizzello F; GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Dig Liver Dis. 2016;48:360-370. [PMID: 26821929 DOI: 10.1016/j.dld.2015.12.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
52 Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:482-513. [PMID: 26725569 DOI: 10.1111/apt.13491] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
53 Shapiro JM, Hagin SE, Shah SA, Bright R, Law M, Moniz H, Giacalone J, Jackvony T, Taleban S, Samad Z. Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients. Dig Dis Sci. 2016;61:1635-1640. [PMID: 26725063 DOI: 10.1007/s10620-015-4010-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
54 Khan HM, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol. 2015;8:293-302. [PMID: 26648749 DOI: 10.2147/ceg.s57248] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
55 Ho G, Boyapati R, Satsangi J. Ulcerative colitis. Medicine 2015;43:276-81. [DOI: 10.1016/j.mpmed.2015.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
56 Wang MC, Zhang LY, Han W, Shao Y, Chen M, Ni R, Wang GN, Wei FX, Zhang YW, Xu XD. PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2014;93:e326. [PMID: 25526490 DOI: 10.1097/md.0000000000000326] [Cited by in Crossref: 45] [Cited by in F6Publishing: 14] [Article Influence: 6.4] [Reference Citation Analysis]
57 Hicks CW, Wick EC, Salvatori R, Ha CY. Perioperative Corticosteroid Management for Patients with Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2015;21:221-8. [DOI: 10.1097/mib.0000000000000185] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Alharbi OR, Azzam NA, Almalki AS, Almadi MA, Alswat KA, Sadaf N, Aljebreen AM. Clinical epidemiology of ulcerative colitis in Arabs based on the Montréal classification. World J Gastroenterol 2014; 20(46): 17525-17531 [PMID: 25516667 DOI: 10.3748/wjg.v20.i46.17525] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
59 Speca S, Dubuquoy L, Desreumaux P. Peroxisome Proliferator–activated Receptor Gamma in the Colon: Inflammation and Innate Antimicrobial Immunity. Journal of Clinical Gastroenterology 2014;48:S23-7. [DOI: 10.1097/mcg.0000000000000253] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
60 Herrlinger KR, Stange EF, Fellermann K. Therapeutic peptides in inflammatory bowel disease. Expert Opin Biol Ther 2014;14:455-66. [PMID: 24450849 DOI: 10.1517/14712598.2014.880109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
61 Beniwal-Patel P, Saha S. The role of integrin antagonists in the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2014;14:1815-23. [PMID: 25288228 DOI: 10.1517/14712598.2014.967209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
62 Sanei MH, Hadizadeh F, Adibi P, Alavi SA. Inflammatory cells' role in acetic acid-induced colitis. Adv Biomed Res 2014;3:193. [PMID: 25337523 DOI: 10.4103/2277-9175.140666] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
63 Chae HB, Jung YS, Park DI, Lee CK, Huh KC, Shin JE, Kim JH, Kim YS, Jung Y, Jung SA, Song HJ, Jang HJ, Hong SN, Kim YH. [Differences in the prognosis according to the periods of diagnosis in ulcerative colitis]. Korean J Gastroenterol 2014;64:93-7. [PMID: 25168051 DOI: 10.4166/kjg.2014.64.2.93] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Naves JE, Llaó J, Ruiz-cerulla A, Romero C, Mañosa M, Lobatón T, Cabré E, Garcia-planella E, Guardiola J, Domènech E. Long-term Comparative Efficacy of Cyclosporine- or Infliximab-based Strategies for the Management of Steroid-refractory Ulcerative Colitis Attacks: . Inflammatory Bowel Diseases 2014;20:1375-81. [DOI: 10.1097/mib.0000000000000101] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
65 Khan NH, Almukhtar RM, Cole EB, Abbas AM. Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease - a nationwide study of 1035 patients. Aliment Pharmacol Ther. 2014;40:374-381. [PMID: 24961751 DOI: 10.1111/apt.12834] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
66 Saibeni S, Meucci G, Papi C, Manes G, Fascì-Spurio F. Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame? Expert Rev Gastroenterol Hepatol 2014;8:949-62. [PMID: 24882015 DOI: 10.1586/17474124.2014.924396] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
67 Kawalec P, Mikrut A, Łopuch S. Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis: Biological therapy for ulcerative colitis. J Gastroenterol Hepatol 2014;29:1159-70. [DOI: 10.1111/jgh.12563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
68 Han W, Xu J, Hu N, Mei Q, Liu M. Early predictors of responses and clinical outcomes of corticosteroid treatment for severe ulcerative colitis. Scandinavian Journal of Gastroenterology 2014;49:424-33. [DOI: 10.3109/00365521.2014.886716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
69 Vavricka SR, Schoepfer AM, Scharl M, Rogler G. Steroid Use in Crohn’s Disease. Drugs 2014;74:313-24. [DOI: 10.1007/s40265-014-0183-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
70 Herfarth H. Are we ready for top-down therapy for inflammatory bowel diseases: con. Expert Review of Gastroenterology & Hepatology 2014;1:249-55. [DOI: 10.1586/17474124.1.2.249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Hare NC, Arnott ID, Satsangi J. Therapeutic options in acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;2:357-70. [DOI: 10.1586/17474124.2.3.357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
72 Iudicibus SD, Lucafò M, Martelossi S, Pierobon C, Ventura A, Decorti G. MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases. World J Gastroenterol 2013; 19(44): 7947-7954 [PMID: 24307788 DOI: 10.3748/wjg.v19.i44.7947] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
73 Lee J, Shin K, Kim J, Lim KS, Jang I, Chung J. Pharmacokinetics, Safety and Tolerability of DA-6034, an Anti-Inflammatory Agent, After Single and Multiple Oral Administrations in Healthy Volunteers. Clin Drug Investig 2014;34:37-42. [DOI: 10.1007/s40261-013-0147-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
74 Ewald PW, Swain Ewald HA. An evolutionary perspective on the causes and treatment of inflammatory bowel disease: . Current Opinion in Gastroenterology 2013;29:350-6. [DOI: 10.1097/mog.0b013e328361f80f] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
75 Khan N, Abbas A, Williamson A, Balart L. Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. Dig Dis Sci. 2013;58:2963-2969. [PMID: 23812861 DOI: 10.1007/s10620-013-2748-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
76 Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol 2013;36:127-46. [PMID: 23433780 DOI: 10.1016/j.gastrohep.2013.01.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
77 Schmidt KJ, Herrlinger KR, Emmrich J, Barthel D, Koc H, Lehnert H, Stange EF, Fellermann K, Büning J. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther. 2013;37:129-136. [PMID: 23121200 DOI: 10.1111/apt.12118] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
78 Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte JM, Stoynov S. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. J Crohns Colitis. 2013;7:636-643. [PMID: 23078909 DOI: 10.1016/j.crohns.2012.09.016] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
79 Saito K, Katsuno T, Nakagawa T, Saito M, Sazuka S, Sato T, Matsumura T, Arai M, Miyauchi H, Matsubara H, Yokosuka O. Predictive factors of response to intravenous ciclosporin in severe ulcerative colitis: the development of a novel prediction formula. Aliment Pharmacol Ther 2012;36:744-54. [DOI: 10.1111/apt.12033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
80 Cucchiara S, Stronati L. Paediatric ulcerative colitis—can we predict proctocolectomy? Nat Rev Gastroenterol Hepatol 2012;9:494-5. [DOI: 10.1038/nrgastro.2012.153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
81 De Cassan C, Fiorino G, Danese S. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects? Dig Dis. 2012;30:368-375. [PMID: 22796798 DOI: 10.1159/000338128] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
82 Ahluwalia JP. Immunotherapy in Inflammatory Bowel Disease. Medical Clinics of North America 2012;96:525-44. [DOI: 10.1016/j.mcna.2012.04.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
83 Naves JE, Domènech E. Amiloidosis sistémica en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2012;35:259-65. [DOI: 10.1016/j.gastrohep.2011.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
84 Cabriada JL. Aféresis en enfermedad inflamatoria intestinal. ¿Una opción válida? Gastroenterología y Hepatología 2012;35:22-31. [DOI: 10.1016/j.gastrohep.2011.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Kim J, Kim HJ, Lee CK, Kim H, Shin AR, Kang KH, Kim MK, Park HJ, Chung HH, Hwang EJ. Predictors of Steroid Treatment Failure and Validation of Previous Models for Severe Attacks of Ulcerative Colitis. Intest Res 2012;10:251. [DOI: 10.5217/ir.2012.10.3.251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
86 Mañosa M, Cabré E, Garcia-planella E, Bernal I, Gordillo J, Esteve M, Zabana Y, Gassull MA, Domènech E. Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids: . Inflammatory Bowel Diseases 2011;17:2497-502. [DOI: 10.1002/ibd.21634] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
87 Cabriada JL, Domènech E, Ibargoyen N, Hernández V, Clofent J, Ginard D, Gutiérrez-Ibarluzea I, Hinojosa J. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. J Gastroenterol. 2012;47:359-365. [PMID: 22105230 DOI: 10.1007/s00535-011-0499-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
88 Garcia-Planella E, Mañosa M, Van Domselaar M, Gordillo J, Zabana Y, Cabré E, López San Román A, Domènech E. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Dig Liver Dis 2012;44:206-10. [PMID: 22079262 DOI: 10.1016/j.dld.2011.10.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
89 McSharry K, Dalzell AM, Leiper K, El-Matary W. Systematic review: the role of tacrolimus in the management of Crohn's disease. Aliment Pharmacol Ther. 2011;34:1282-1294. [PMID: 21999607 DOI: 10.1111/j.1365-2036.2011.04873.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
90 Desmond AN, Shanahan F. Managing chronic disease in Ireland: hospital admission rates and clinical outcomes in a large ulcerative colitis population. Ir J Med Sci. 2012;181:65-71. [PMID: 21947686 DOI: 10.1007/s11845-011-0760-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
91 Jakobsen C, Munkholm P, Paerregaard A, Wewer V. Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators—A population-based study: . Inflammatory Bowel Diseases 2011;17:1731-40. [DOI: 10.1002/ibd.21559] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
92 Krupoves A, Mack DR, Seidman EG, Deslandres C, Bucionis V, Amre DK. Immediate and long-term outcomes of corticosteroid therapy in pediatric Crohn's disease patients. Inflamm Bowel Dis 2011;17:954-62. [PMID: 20684012 DOI: 10.1002/ibd.21415] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
93 Hanauer SB, Wald A. Acute and chronic megacolon. Curr Treat Options Gastroenterol 2007;10:237-47. [PMID: 17547862 DOI: 10.1007/s11938-007-0017-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
94 Mañosa M, García V, Castro L, García-Bosch O, Chaparro M, Barreiro-de Acosta M, Carpio D, Aguas M. Methotrexate in ulcerative colitis: a Spanish multicentric study on clinical use and efficacy. J Crohns Colitis 2011;5:397-401. [PMID: 21939912 DOI: 10.1016/j.crohns.2011.03.012] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
95 Serra I, Oller B, Mañosa M, Naves JE, Zabana Y, Cabré E, Domènech E. Systemic amyloidosis in inflammatory bowel disease: retrospective study on its prevalence, clinical presentation, and outcome. J Crohns Colitis. 2010;4:269-274. [PMID: 21122515 DOI: 10.1016/j.crohns.2009.11.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
96 Duricova D, Pedersen N, Lenicek M, Jakobsen C, Lukas M, Wewer V, Munkholm P. The clinical implication of drug dependency in children and adults with inflammatory bowel disease: A review. Journal of Crohn's and Colitis 2011;5:81-90. [DOI: 10.1016/j.crohns.2010.12.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
97 Ho G, Lees C, Satsangi J. Ulcerative colitis. Medicine 2011;39:224-8. [DOI: 10.1016/j.mpmed.2011.01.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
98 Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659, quiz 660. [PMID: 21407183 DOI: 10.1038/ajg.2011.73] [Cited by in Crossref: 374] [Cited by in F6Publishing: 391] [Article Influence: 34.0] [Reference Citation Analysis]
99 Buchanan J, Wordsworth S, Ahmad T, Perrin A, Vermeire S, Sans M, Taylor J, Jewell D. Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. J Crohns Colitis 2011;5:301-16. [PMID: 21683300 DOI: 10.1016/j.crohns.2011.02.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
100 López-Serrano P, Pérez-Calle JL, Fernández-Rodríguez C. Ulcerative colitis in Madrid, Spain: current management. Inflamm Bowel Dis 2010;16:1826-7. [PMID: 20186938 DOI: 10.1002/ibd.21237] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Bello C, Belaiche J, Louis E, Reenaers C. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. J Crohns Colitis. 2011;5:196-202. [PMID: 21575881 DOI: 10.1016/j.crohns.2010.12.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
102 Krupoves A, Mack D, Seidman E, Deslandres C, Amre D. Associations between variants in the ABCB1 (MDR1) gene and corticosteroid dependence in children with Crohn’s disease. Inflamm Bowel Dis. 2011;17:2308-2317. [PMID: 21987299 DOI: 10.1002/ibd.21608] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
103 Ardizzone S, Cassinotti A, Duca P, Mazzali C, Penati C, Manes G, Marmo R, Massari A, Molteni P, Maconi G, Porro GB. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9: 483-489. e3. [PMID: 21195796 DOI: 10.1016/j.cgh.2010.12.028] [Cited by in Crossref: 184] [Cited by in F6Publishing: 174] [Article Influence: 15.3] [Reference Citation Analysis]
104 D’Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212; quiz 213. [PMID: 21045814 DOI: 10.1038/ajg.2010.392] [Cited by in Crossref: 263] [Cited by in F6Publishing: 280] [Article Influence: 21.9] [Reference Citation Analysis]
105 Thanaraj S, Hamlin PJ, Ford AC. Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis. Aliment Pharmacol Ther. 2010;32:1297-1306. [PMID: 21050231 DOI: 10.1111/j.1365-2036.2010.04490.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
106 Ford AC, Khan KJ, Talley NJ, Moayyedi P. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol 2011;106:413-20. [PMID: 20717106 DOI: 10.1038/ajg.2010.317] [Cited by in Crossref: 75] [Cited by in F6Publishing: 57] [Article Influence: 6.3] [Reference Citation Analysis]
107 Portela F, Magro F, Lago P, Cotter J, Cremers I, de Deus J, Vieira A, Lopes H, Caldeira P, Barros L. Ulcerative colitis in a Southern European country: a national perspective. Inflamm Bowel Dis. 2010;16:822-829. [PMID: 19824069 DOI: 10.1002/ibd.21119] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
108 Feldman PA, Wolfson D, Barkin JS. Medical management of Crohn's disease. Clin Colon Rectal Surg 2007;20:269-81. [PMID: 20011423 DOI: 10.1055/s-2007-991026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
109 Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am. 2009;38:577-594. [PMID: 19913203 DOI: 10.1016/j.gtc.2009.07.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
110 Dignass A, Van Assche G, Lindsay J, Lémann M, Söderholm J, Colombel J, Danese S, D'hoore A, Gassull M, Gomollón F, Hommes D, Michetti P, O'morain C, Öresland T, Windsor A, Stange E, Travis S. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. Journal of Crohn's and Colitis 2010;4:28-62. [DOI: 10.1016/j.crohns.2009.12.002] [Cited by in Crossref: 981] [Cited by in F6Publishing: 886] [Article Influence: 81.8] [Reference Citation Analysis]
111 Hanauer SB. Positioning biologic agents in the treatment of Crohn's disease. Inflamm Bowel Dis 2009;15:1570-82. [PMID: 19309716 DOI: 10.1002/ibd.20918] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
112 Parente F, Molteni M, Marino B, Colli A, Ardizzone S, Greco S, Sampietro G, Foschi D, Gallus S. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis? Am J Gastroenterol. 2010;105:1150-1157. [PMID: 19997096 DOI: 10.1038/ajg.2009.672] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 6.2] [Reference Citation Analysis]
113 Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Med Clin North Am. 2010;94:1-18. [PMID: 19944795 DOI: 10.1016/j.mcna.2009.08.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
114 Frizelle FA, Ing A, Gearry RB, Whitehead M, Faragher IG, Dobbs B. Immunomodulation does not alter histology in resected Crohn’s disease. Tech Coloproctol. 2009;13:295-300. [PMID: 19774438 DOI: 10.1007/s10151-009-0538-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
115 Zhang Z, Kennedy H. Ulcerative colitis: current medical therapy and strategies for improving medication adherence. Eur J Gastroenterol Hepatol. 2009;21:1-8. [PMID: 19011573 DOI: 10.1097/MEG.0b013e32830bfb88] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
116 Papi C, Aratari A, Moretti A, Mangone M, Margagnoni G, Koch M, Capurso L. Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig Dis Sci. 2010;55:2002-2007. [PMID: 19937467 DOI: 10.1007/s10620-009-0962-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
117 Huang LJ, Zhu Q, Lei M, Cao Q. Current use of immunosuppressive agents in inflammatory bowel disease patients in East China. World J Gastroenterol 2009; 15(24): 3055-3059 [PMID: 19554661 DOI: 10.3748/wjg.15.3055] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
118 Bossa F, Colombo E, Andriulli A, Annese V. Treatment of steroid-naive ulcerative colitis. Expert Opinion on Pharmacotherapy 2009;10:1449-60. [DOI: 10.1517/14656560902973728] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
119 Juyal G, Midha V, Amre D, Sood A, Seidman E, Thelma BK. Associations between common variants in the MDR1 (ABCB1) gene and ulcerative colitis among North Indians. Pharmacogenet Genomics. 2009;19:77-85. [PMID: 19005421 DOI: 10.1097/fpc.0b013e32831a9abe] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
120 Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P. Azathioprine Is Superior to Budesonide in Achieving and Maintaining Mucosal Healing and Histologic Remission in Steroid-Dependent Crohnʼs Disease: . Inflammatory Bowel Diseases 2009;15:375-82. [DOI: 10.1002/ibd.20777] [Cited by in Crossref: 109] [Cited by in F6Publishing: 105] [Article Influence: 8.4] [Reference Citation Analysis]
121 Chow DK, Sung JJ, Tsoi KK, Wong VW, Wu JC, Leong RW, Chan FK. Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study. Aliment Pharmacol Ther. 2009;29:843-854. [PMID: 19154567 DOI: 10.1111/j.1365-2036.2009.03944.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
122 Nakahara S, Arimura Y, Saito K, Goto A, Motoya S, Shinomura Y, Miyamoto A, Imai K. Association of SLC22A4/5 Polymorphisms with Steroid Responsiveness of Inflammatory Bowel Disease in Japan. Diseases of the Colon & Rectum 2008;51:598-603. [DOI: 10.1007/s10350-008-9208-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
123 Travis S, Stange E, Lémann M, Øresland T, Bemelman W, Chowers Y, Colombel J, D'haens G, Ghosh S, Marteau P, Kruis W, Mortensen N, Penninckx F, Gassull M. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis 2008;2:24-62. [DOI: 10.1016/j.crohns.2007.11.002] [Cited by in Crossref: 378] [Cited by in F6Publishing: 343] [Article Influence: 27.0] [Reference Citation Analysis]
124 Zhu Q, Cao Q, Si JM. Quality of care for patients with inflammatory bowel disease in East China. World J Gastroenterol 2008; 14(4): 612-616 [PMID: 18203296 DOI: 10.3748/wjg.14.612] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
125 Irving PM, Gearry RB, Sparrow MP, Gibson PR. Review article: appropriate use of corticosteroids in Crohn's disease. Aliment Pharmacol Ther 2007;26:313-29. [PMID: 17635367 DOI: 10.1111/j.1365-2036.2007.03379.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
126 Gisbert JP, Gomollón F. [Common errors in the management of the seriously ill patient with inflammatory bowel disease]. Gastroenterol Hepatol 2007;30:294-314. [PMID: 17493441 DOI: 10.1157/13101982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
127 López San Román A, Rivero Fernández M. Estado actual del tratamiento de la enfermedad inflamatoria intestinal. Revista Clínica Española 2007;207:298-300. [DOI: 10.1157/13106853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
128 Ho G, Lees C, Satsangi J. Ulcerative colitis. Medicine 2007;35:277-82. [DOI: 10.1016/j.mpmed.2007.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
129 Hoie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, Tsianos E, Beltrami M, Odes S, Munkholm P. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507-515. [PMID: 17258717 DOI: 10.1053/j.gastro.2006.11.015] [Cited by in Crossref: 177] [Cited by in F6Publishing: 172] [Article Influence: 11.1] [Reference Citation Analysis]